Cambridge: Pitmans acts on Lab 21 deal

Pitmans, a leading commercial law firm in the Thames Valley and London, has acted on behalf of Lab 21 in its acquisition of Biotec Laboratories for an undisclosed sum.

Cambridge-based Lab 21 is a global provider of state-of-the-art diagnostic products and services, supporting drug discovery and healthcare. Its customers include healthcare providers, pharmaceutical and biotechnology companies. The acquisition was led by Pitmans corporate partner Philip Weaver.

Commenting on the acquisition, Graham Mullis, CEO of Lab 21, said: “The acquisition of Biotec Laboratories will give us a good platform from which to build our infectious disease diagnostic list portfolio. There were several testing aspects to the transaction which Pitmans handled very well.”

Weaver commented: “We were very pleased that Lab 21 instructed Pitmans to act on this transaction. The fact that Lab 21 is based in Cambridge demonstrates that our client base is not limited solely to the Thames Valley. We look forward to assisting Lab 21 further with its ambitious growth aspirations.”